A California MDL judge overseeing claims that four Type 2 diabetes drugs increased the risk of pancreatic cancer has dismissed at least 750 lawsuits under a rarely used analysis of the federal preemption doctrine.  In re Incretin-Based Therapies Products Liability Litigation, slip op. (S.D. Cal. Nov. 9, 2015) (the “Order”). In doing so, the opinion … Continue reading